How to Develop a National Formulary Based on the WHO Model Formulary - A Practical Guide
(2004; 45 pages) Ver el documento en el formato PDF
Índice de contenido
Ver el documentoAbbreviations
Abrir esta carpeta y ver su contenido1 INTRODUCTION
Abrir esta carpeta y ver su contenido2 OVERVIEW OF THE NATIONAL FORMULARY PROCESS
Abrir esta carpeta y ver su contenido3 DEVELOPING THE PRELIMINARY INFORMATION SECTION
Abrir esta carpeta y ver su contenido4 DEVELOPMENT OF THERAPEUTIC INFORMATION AND MONOGRAPHS USING THE WHO MODEL FORMULARY
Abrir esta carpeta y ver su contenido5 ADDITIONAL SOURCES OF INFORMATION
Abrir esta carpeta y ver su contenido6 DEVELOPING SPECIFIC INFORMATION SECTIONS
Abrir esta carpeta y ver su contenido7 PRODUCTION, DISTRIBUTION AND IMPLEMENTATION
Abrir esta carpeta y ver su contenido8 EVALUATION
Cerrar esta carpeta9 REVIEW AND UPDATE
Ver el documentoPlanning for review
Ver el documentoHow frequently does the national formulary need to be reviewed?
Cerrar esta carpetaReview process
Ver el documentoIdentification of areas in need of change
Ver el documentoDrafting of updated texts for areas where change is necessary
Ver el documentoUpdating texts based on the WHO model formulary
Ver el documentoUpdating texts containing locally added information
Ver el documentoApproval by the national formulary committee and expert advisers
Ver el documentoREFERENCES
 

Drafting of updated texts for areas where change is necessary

The review process is similar to the development process (see Chapter 2) and will need careful planning and budgeting. A review committee should be set up and each chapter carefully assessed by an expert subcommittee charged with identifying information that needs changing either in the drug monographs, clinical guidance or additional information sections. This will include consideration of any suggestions received from users of the formulary.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013